IOBT

IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel immune-modulating cancer therapies based on its T-win technology platform. The company's approach focuses on disarming immunosuppressive cells in the tumor microenvironment to enable the immune system to fight cancer more effectively. IO Biotech's lead candidates are being evaluated in clinical trials for various solid tumor types, including melanoma and lung cancer. The company is headquartered in Copenhagen, Denmark, with additional operations in the United States.